🧬 BioMed Pulse · 2026-10-29 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Thursday, October 29, 2026 — 02:00 UTC

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now spread to Kenya and Nigeria, making it the largest Ebola outbreak ever recorded in DRC history, with cross-border transmission accelerating.

Mood: Grave on the outbreak front; cautiously active on the approvals and trials side.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC, KENYA, NIGERIA

  • As of October 23, 2026, the WHO confirmed Bundibugyo virus disease (BVD) has spread beyond DRC to both Kenya and Nigeria via imported cases, marking a significant new geographic expansion. [1]
  • Kenya confirmed a laboratory-positive BVD case in a traveler who transited Uganda from DRC and was hospitalized; the case is the first confirmed imported BVD case in Kenya. [2]
  • As of the September 25 update, the DRC outbreak had reached two additional health zones including Bulu in the new province of Sud Ubangi, in the country's northwest, suggesting spread toward Central African Republic border areas. [3]
  • WHO's August 14 report labeled this the largest Ebola outbreak ever reported in DRC, expanding faster than any previous Ebola outbreak on record. [4]
  • As of August 28, 60 health zones across six provinces — Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo — were affected, with six additional health zones newly reporting cases in that update window. [5]
  • The outbreak was declared on May 15, 2026, by the DRC Ministry of Public Health after Bundibugyo virus (a distinct filovirus species from Ebola Zaire) was confirmed in both DRC and Uganda. [6]
  • WHO and CDC have both mobilized international response operations; enhanced Ebola airport screening was established at Washington Dulles and Atlanta airports in May 2026. [7] [8]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On October 2, 2026, WHO was notified via media reports of the death of an employee at the Irkutsk Antiplague Research Institute of Siberia and the Far East (APRI) following severe pneumonia; the cause remains under investigation. [9]
  • The identity of the pathogen and any potential occupational exposure link to select agents held at APRI have not been publicly confirmed as of the WHO Disease Outbreak News posting on October 10. [9]

MERS-CoV — SAUDI ARABIA

  • Between January 1 and October 5, 2026, Saudi Arabia reported 8 laboratory-confirmed MERS-CoV cases including 1 death, spread across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh (2 cases), and Tabuk. [10]
  • MERS-CoV continues to circulate at low endemic levels on the Arabian Peninsula, driven primarily by camel-to-human transmission. [10]

LISTERIA — PREPARED MEALS (ONGOING, U.S.)

  • CDC as of October 30, 2026, is still urging consumers to check refrigerators and freezers for recalled prepared meal products linked to ongoing Listeria illnesses, noting cases continue despite earlier product recalls.
  • The outbreak expanded in late September 2025 to include additional prepared food products; 3 additional illnesses and 1 additional death were reported in that update.

SALMONELLA — MORINGA LEAF PRODUCTS (U.S.)

  • The moringa leaf supplement Salmonella cluster has grown significantly: as of January 29, 2026, 65 people in 28 states were reported sick, up from the initial 11 cases in 7 states first flagged in October 2025.
  • In February 2026, CDC confirmed the strain is extensively drug-resistant (XDR) Salmonella, with 3 hospitalizations and no deaths as of that update.

DRUG-RESISTANT BACTERIA — U.S. SURVEILLANCE

  • A CDC report published September 23, 2025, documented a dramatic increase in dangerous drug-resistant bacteria nationally, adding urgency to antimicrobial stewardship efforts.

🧬 LONGEVITY & AGING

GLP-1 RECEPTOR AGONISTS VS. SLEEVE GASTRECTOMY — NEW OBSERVATIONAL STUDY

  • A newly registered ClinicalTrials.gov observational study (NCT07901777, posted October 28, 2026) will compare 2-year weight loss outcomes between adults starting GLP-1 receptor agonist medications and adults who previously underwent laparoscopic sleeve gastrectomy, targeting the obesity-aging overlap.
  • Weight and metabolic trajectory over 24 months is the primary comparison; findings could help clarify whether pharmacological GLP-1 intervention rivals surgical approaches for long-term cardiometabolic aging risk reduction.

VIBEGRON FOR ENERGY METABOLISM AND COGNITIVE FUNCTION IN AGING

  • Trial NCT06987383 (VETRA study) is a 12-week randomized, double-blind, placebo-controlled study testing Vibegron (GEMTESA, a beta-3 adrenergic receptor agonist) to improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
  • Beta-3 adrenergic receptor agonism activates brown adipose tissue thermogenesis, a pathway linked to metabolic rejuvenation in aging biology.

SAINT TMS THERAPY FOR MEMORY IN OLDER ADULTS WITH TREATMENT-RESISTANT DEPRESSION

  • Trial NCT07876908 is testing Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a high-dose intermittent theta-burst transcranial magnetic stimulation protocol, specifically for memory and cognitive improvement in adults aged 65 and older with treatment-resistant depression.
  • Depression in older adults is a known accelerant of cognitive decline and biological aging; the trial addresses whether reversing treatment-resistant depression via TMS can preserve cognitive function.

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID

  • Phase I trial NCT07388550 (PD1-PASC I) is testing pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, as a treatment for neurological post-acute sequelae of SARS-CoV-2 (neuro-PASC), registered October 28, 2026.
  • The hypothesis is that persistent viral antigen or immune dysregulation driving neuro-PASC may respond to PD-1 pathway reactivation, paralleling mechanisms seen in chronic viral infections associated with accelerated neurological aging.

DELIRIUM AND ANALGESIA IN ELDERLY SURGICAL PATIENTS

  • Trial NCT07849517 will evaluate whether different postoperative analgesic strategies affect rates of postoperative delirium in elderly patients undergoing total knee arthroplasty — delirium being a major driver of accelerated cognitive decline and mortality in older adults.

HEART FAILURE MULTI-SCALE PHENOTYPING (MAP-HEART)

  • Trial NCT06280820 (MAP-HEART) is enrolling patients to compare blood, imaging, and clinical phenotypes in over 6.5 million heart failure patients in the U.S., aiming to clarify how HF develops and progresses — a key aging-related disease mechanism.

💊 NEW CURES & APPROVALS

HIBSAGO (BEPIROVIRSEN) — GLAXOSMITHKLINE LLC

  • openFDA records a new original approval (ORIG AP) for HIBSAGO, whose active ingredient is bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) RNA, sponsored by GlaxoSmithKline LLC (NDA221276).
  • Bepirovirsen works by silencing multiple HBV RNA transcripts simultaneously, including pregenomic RNA and surface antigen mRNA, offering a functional cure mechanism distinct from current nucleoside analog therapies.

REBLOZYL (LUSPATERCEPT-AAMT) SUPPLEMENTAL APPROVAL — CELGENE CORP

  • Celgene Corp received a supplemental approval (SUPPL AP) for REBLOZYL (luspatercept-aamt, BLA761136), an activin receptor ligand trap that reduces ineffective erythropoiesis, used in anemia associated with beta-thalassemia and myelodysplastic syndromes.

SOLIRIS (ECULIZUMAB) AND ULTOMIRIS (RAVULIZUMAB-CWVZ) SUPPLEMENTAL APPROVALS — ALEXION PHARMA

  • Alexion Pharmaceuticals received supplemental approvals for both SOLIRIS (eculizumab, BLA125166) and ULTOMIRIS (ravulizumab-cwvz, BLA761108), both complement C5 inhibitors used in rare hematologic and neurological diseases including paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis.

BRIVARACETAM GENERIC — ZYDUS LIFESCIENCES

  • Zydus Lifesciences received an original ANDA approval (ANDA221301) for generic brivaracetam, a synaptic vesicle protein 2A (SV2A) ligand used as an adjunctive therapy for partial-onset seizures in adults and adolescents.

ZYVOX (LINEZOLID) SUPPLEMENTAL APPROVALS — PFIZER

  • Pfizer received three separate supplemental approvals across NDA021130, NDA021131, and NDA021132 for linezolid (ZYVOX), an oxazolidinone-class antibiotic with activity against vancomycin-resistant Enterococcus and MRSA, relevant against drug-resistant bacterial trends flagged in CDC's September 2025 report.

🧪 CLINICAL TRIALS

RILZABRUTINIB FOR GRAVES DISEASE — PHASE 2

  • Trial NCT06984627 is a parallel-group, Phase 2, 2-arm study of rilzabrutinib (a Bruton tyrosine kinase inhibitor) in adults aged 18 and older with Graves' disease, including those with Graves' orbitopathy, measuring efficacy and safety across two doses over a defined treatment and screening window.

ZOPAPOGENE IMADENOVEC FOR PEDIATRIC RECURRENT RESPIRATORY PAPILLOMATOSIS

  • Trial NCT07901738 is studying zopapogene imadenovec, an HPV-targeted therapeutic, for recurrent respiratory papillomatosis (RRP) caused by HPV types 6 or 11 in children; RRP causes wart-like airway growths requiring repeated surgeries.
  • A companion adult trial (NCT07756840) is evaluating the combination of bevacizumab plus PRGN-2012 immunotherapy for RRP in adults at the NIH.

INHALED AZACYTIDINE COMBINED WITH DURVALUMAB FOR EARLY-STAGE NSCLC — AZA-AEGEAN

  • Trial NCT06694454 (AZA-AEGEAN) is testing neoadjuvant inhaled azacytidine (an epigenetic DNMT inhibitor) combined with platinum-based chemotherapy and durvalumab (anti-PD-L1) as a combined epigenetic-immunotherapy regimen for operable early-stage non-small cell lung cancer.

DIABETES AND OBESITY CLINICAL SPECTRUM STUDY — NIH

  • Trial NCT07388537 at NIH is evaluating the full clinical spectrum of diabetes and obesity across youth and adults, specifically examining how early-onset disease drives faster progression and increased mortality risk — directly relevant to lifespan compression in younger cohorts.

📢 PUBLIC HEALTH

LISTERIA CONSUMER ALERT — PREPARED MEALS STILL IN HOMES

  • CDC urges all U.S. consumers to immediately check refrigerators and freezers for recalled prepared meal products linked to ongoing Listeria illness; do not eat recalled products even if they appear and smell normal.

RABIES ACTIVITY RISING — U.S.

  • CDC issued a statement on September 10, 2026, flagging increases in animal rabies activity across the U.S. and associated rises in human exposures, urging post-exposure prophylaxis evaluation for anyone bitten or scratched by wild animals.

TICK BITE ER VISITS ELEVATED — U.S.

  • CDC data from April 2026 showed weekly emergency department visits for tick bites running higher than usual for the season, with tick-borne disease risk elevated across multiple U.S. regions.

U.S. WHO WITHDRAWAL COMPLETE — PUBLIC HEALTH GOVERNANCE NOTE

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026; WHO expressed regret, stating the withdrawal "makes both the United States and the world less safe."
  • The withdrawal affects U.S. participation in global disease surveillance, outbreak reporting, and coordinated pandemic response infrastructure at a time when the DRC Ebola outbreak and a Russian pneumonia cluster of undetermined origin are both active.

KINDERGARTEN VACCINATION RATES — SLIGHT DECLINE

  • CDC data released August 17, 2026, showed U.S. kindergarten vaccination coverage remains high overall but recorded a 0.1% decline, a trend worth monitoring given active measles circulation and ongoing outbreak risk.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  10. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261029-02-v120 · 2026-10-29 02:01 UTC · pulse.uzylab.com